Atlantic City, New Jersey, U.S., September 28, 2026
SetPoint Medical has announced an important clinical-access milestone following the completion of the first SetPoint® System procedures in Southern New Jersey. The procedures were performed by Rudy Rahme, MD, a neurosurgeon with Global Neurosciences Institute (GNI), at AtlantiCare Regional Medical Center in Atlantic City, New Jersey. The expansion brings SetPoint Therapy to eligible adults living with moderately to severely active rheumatoid arthritis (RA) across Southern New Jersey and neighboring regions. The SetPoint System is a U.S. FDA-approved neuroimmune modulation therapy that uses an implanted neurostimulator to activate pathways involving the vagus nerve.
SetPoint System Expands Into Southern New Jersey
The SetPoint System consists of a miniaturized implantable neurostimulator and a wireless charger designed for at-home use. The device is indicated for adults with moderately to severely active RA who have experienced an inadequate response, loss of response or intolerance to one or more biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs). The latest procedures extend availability of the technology to patients in Southern New Jersey, Delaware and Eastern Pennsylvania through a growing network of rheumatology practices. The first procedures were performed through collaboration between Global Neurosciences Institute, AtlantiCare and regional rheumatology providers, bringing together neurosurgical and rheumatology expertise. According to SetPoint, the device is implanted on the vagus nerve in the neck through a surgical procedure, after which patients use the wireless charger as part of the therapy. The approach provides a device-based treatment option for patients whose RA remains active despite previous drug therapy. The expansion is part of SetPoint Medical’s broader effort to increase access to its neuroimmune-modulation platform. The company describes its technology as a new therapeutic category that seeks to influence the body’s natural neuroimmune pathways rather than directly delivering an immunosuppressive drug. Individual treatment outcomes can vary, and the device carries surgical and other potential risks that are described in its safety information.
Neuroimmune Modulation Targets RA Inflammation
Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by inflammation of the synovial lining of joints. Persistent inflammation can cause pain, swelling, stiffness and progressive structural damage. Although biologic and targeted synthetic therapies have expanded treatment options, some patients do not achieve adequate disease control or cannot tolerate available medicines. SetPoint is being positioned as a non-pharmacological treatment approach for eligible patients with active RA. The SetPoint System is designed to stimulate the vagus nerve, which plays a role in communication between the nervous and immune systems. SetPoint Medical says activation of this pathway is intended to engage endogenous anti-inflammatory mechanisms and influence immune activity. The company describes the technology as aiming to restore the body’s immunologic setpoint rather than suppressing immune function through conventional systemic immunosuppressive medicines. These mechanisms represent the company’s therapeutic rationale and should be distinguished from established clinical outcomes. The system’s expansion also reflects growing interest in bioelectronic medicine and neuromodulation as potential approaches to chronic inflammatory diseases. Rather than relying solely on pharmaceutical intervention, these technologies seek to use electrical stimulation to influence biological signaling pathways. For patients who have inadequate responses to existing therapies, device-based approaches may represent another area of clinical development.
Advertisement
SetPoint Builds Regional Clinical Access
The Southern New Jersey procedures expand a growing network of clinicians able to provide SetPoint Therapy. SetPoint reported that patients can access the treatment through rheumatology practices including Lebanon Internal Medicine Associates in Pennsylvania and Arthritis, Rheumatic & Bone Disease Associates, an affiliate of Trabecular Medical Group with locations across Southern New Jersey. The coordinated model brings rheumatologists and neurosurgeons together to support patient evaluation, implantation and ongoing care. For cGxP.wire, the milestone is significant because it demonstrates the movement of neuroimmune modulation from medical-device development into broader clinical practice for rheumatoid arthritis.
SetPoint Medical is also planning to evaluate its neurostimulation platform in additional autoimmune conditions, including multiple sclerosis and Crohn’s disease, although those applications remain part of the company’s development plans rather than established indications. The first procedures in Southern New Jersey therefore represent an expansion of access to an FDA-approved device-based RA therapy and highlight the growing intersection of neurosurgery, rheumatology, neuromodulation and immunology in chronic disease management.
Source: SetPoint Medical press release
